📧 FREE CASE EVALUATION: Info@GLP1Lawsuits.com
中文
← Back to Main Page

Nearly 25,000 Emergency Visits Linked to Semaglutide

Latest GLP-1 legal updates and medical findings.

• Annals of Internal Medicine / Healio Gastroenterology

Nearly 25,000 Emergency Visits Linked to Semaglutide

Most patients arrived with persistent vomiting, dehydration, or abdominal pain after self-injecting compounded or high doses.

24,499
Estimated ER visits
63%
Female patients
48%
Needed IV fluids

Study overview

Researchers pulled de-identified emergency department data from 2021 through 2023.

Cases were flagged when semaglutide was listed as the primary or secondary suspect drug.

Symptoms driving ER care

Top complaints included intractable vomiting, abdominal pain, rapid heart rate, and severe constipation.

One in five visits involved patients who mixed alcohol or other appetite suppressants with GLP-1 drugs.

Compounded products appear frequently

Clinicians noted that many syringes lacked FDA-approved labeling, making it difficult to verify strength.

Dose miscalculations—especially among telehealth clinics—were cited in 31% of the encounters.

How this feeds litigation

ER notes provide time-stamped evidence that injuries occurred soon after injections.

Attorneys can subpoena hospital pharmacy logs to trace whether compounded products were used.

When to seek emergency care

  • Persistent vomiting lasting more than 24 hours
  • Signs of dehydration such as dizziness or reduced urination
  • Sharp abdominal pain paired with bloating or inability to pass stool

Need Legal Guidance Right Now?

Share discharge summaries with our team so we can match them to dosing histories and pursue responsible manufacturers or compounders.

Our intake team responds within one business day.

Start Free Case Evaluation

Find out if you have a GLP-1 claim

If you experienced serious side effects after using GLP-1 medications, you may be eligible for compensation.

Start your free case evaluation